Market Overview

Bristol-Myers Squibb Presents Phase II Hepatitis C Data


Squibb Company (NYSE: BMY) announced Sunday new Phase II data
demonstrating that the dual regimen of the investigational NS5A
replication complex inhibitor daclatasvir (DCV) and the investigational
NS3 protease inhibitor asunaprevir (ASV), without interferon or
ribavirin, achieved high rates of sustained virologic response 12 weeks
post-treatment (SVR12) in patients with genotype 1b (GT1b)
hepatitis C virus (HCV) who were prior null responders to alfa
interferon and ribavirin (alfa/RBV). In this study, the DCV/ASV Dual
regimen achieved SVR12 in 78% (14/18) and 65% (13/20) of GT1b
patients when asunaprevir was dosed twice daily (Group A1) or once daily
(Group A2), respectively.

These results were presented today at the American Association

See full press release

Posted-In: News Guidance Management Global


Related Articles (BMY)

View Comments and Join the Discussion!